ClinicalTrials.gg

Program

GENSCI120

A development code. Also written as “GenSci120”, “GenSci120 150 mg” and “GenSci120 600 mg”.

Its studies are mostly in Arthritis, Rheumatoid · Autoimmune Diseases, led by Changchun GeneScience Pharmaceutical.

Furthest: phase 2, since Feb 4, 20263 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical32 open or runningphase 2since Feb 4, 2026Jan 22, 2025Sep 2027phase 2 · NCT07423533

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 22, 2025First study: phase 1 study in Autoimmune DiseasesFirst studyNCT06827457 · 58 enrolled · China
  2. Jun 10, 2025Phase 1 study in Arthritis, RheumatoidNCT07040930 · 30 planned · China
  3. Feb 4, 2026Phase 2 study in Arthritis, RheumatoidPhase 2 reachedNCT07423533 · 450 planned · China

Ahead

  1. Sep 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07423533

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07423533Arthritis, Rheumatoid · China2RecruitingSep 2027450
NCT07040930Arthritis, Rheumatoid · China1RecruitingJul 5, 202630
NCT06827457Autoimmune Diseases · China1CompletedNov 27, 202558

How it is read

Names in the registry

  • “GenSci120”, 2 entries
  • “GenSci120 150 mg”, 1 entry
  • “GenSci120 600 mg”, 1 entry
  • “GenSci120 1000 mg”, 1 entry

Codes read as this program: GENSCI120.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.